NCT06696079 Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation
| NCT ID | NCT06696079 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rahul Raj |
| Condition | Chronic Subdural Hematoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 332 participants |
| Start Date | 2025-07-07 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 332 participants in total. It began in 2025-07-07 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural hematoma. The main questions it aims to answer are: * Does anticoagulation resumption 5 days after surgery as compared to 30 days after surgery result in fewer thromboembolic complications, without increasing the risk for bleeding? * Does anticoagulation resumption 5 days after surgery as compared to 30 days after surgery affect the risk of reoperation, functional outcome, mortality, and healthcare use? Researchers will compare early anticoagulation resumption (5 days) and late anticoagulation resumption (30 days) after chronic subdural hematoma surgery. Participants will either resume the medication 5 days or 30 days after the surgery. The participants will be followed up for 3 months after the surgery.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years. * Patients with a symptomatic unilateral or bilateral CSDH requiring burr-hole evacuation with drainage (CSDH is predominantly hypodense or isodense on imaging \[CT/MRI\]; clinical symptoms attributable to the CSDH; patients with bilaterally operated CSDHs will be treated with the same protocol on both sides and analyzed as a single study participant). * Patients that are on an oral anticoagulation medication due to permanent, persistent or paroxysmal spontaneous atrial fibrillation previously known * Randomization done within 4 days of the surgery Exclusion Criteria: * Intraoperative or immediate postoperative hemorrhagic complication * CSDH requiring surgical treatment other than burr-hole evacuation (e.g. craniotomy) * Prior CSDH surgery within 12 months * Cerebrospinal fluid shunt * CSDH is in an arachnoid cyst * If the operated hematoma is revealed to be a cerebrospinal fluid collection (hygroma) * Conditions other than atrial fibrillation that require anticoagulation, including therapeutical dose of low molecular-weight heparin or heparin (for example, pulmonary embolism, deep vein thrombosis, hypercoagulability syndromes) * Mechanical heart valve(s) * Moderate or severe mitral stenosis (other valvular diseases and biological valves are eligible) * Contraindication to anticoagulation medication (for example bleeding disorder, documented high risk of fall \[e.g. due to severe alcoholism\], severe thrombocytopenia, severe anemia) * Concomitant use of antiplatelet medication * Moderate to severe renal insufficiency (creatinine clearance \<30 ml/min or on dialysis) * Not a permanent resident in Finland (for Finnish patients) or not a permanent resident in Region Stockholm (for Swedish patients)
Contact & Investigator
Rahul Raj, MD, PhD
STUDY CHAIR
Helsinki University Hospital & University of Helsinki
Frequently Asked Questions
Who can join the NCT06696079 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Subdural Hematoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06696079 currently recruiting?
Yes, NCT06696079 is actively recruiting participants. Contact the research team at rahul.raj@hus.fi for enrollment information.
Where is the NCT06696079 trial being conducted?
This trial is being conducted at Oulu, Finland, Kuopio, Finland, Tampere, Finland, Turku, Finland and 2 additional locations.
Who is sponsoring the NCT06696079 clinical trial?
NCT06696079 is sponsored by Rahul Raj. The principal investigator is Rahul Raj, MD, PhD at Helsinki University Hospital & University of Helsinki. The trial plans to enroll 332 participants.